Among patients 45–60 years, high-dose cytarabine was also associated with significant improvements in CR and 6-year EFS rates, as well as a trend for better survival among patients with FLT3-ITD AML or poor prognosis karyotypes. The gene discussed is FLT3; the disease is acute myeloid leukemia.